SIRIUS
2014
Mepolizumab as Oral-Corticosteroid-Sparing Therapy
In 135 patients with OCS-dependent severe eosinophilic asthma, mepolizumab 100 mg SC every 4 weeks reduced maintenance oral corticosteroid dose compared with placebo.
Result
- Absolute difference
- 50 points
- NNT
- 2
Absolute difference and NNT are derived from the event rates.
Also reported: Exacerbations -32%.
- Subtopic
- OCS sparing
- Design
- RCT
- Relevance
- Supporting: context rather than must-know.
- Cited in
- ERS/ATS 2020 Severe Asthma
- Source
- Bel EH, et al. N Engl J Med. 2014;371(13):1189-1197.doi 10.1056/NEJMoa1403291
Discussion & critique
Made OCS sparing a key indication for anti-IL-5 biologics.